Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Kupfer

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
American Heart Journal|May 16, 2016
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trialYuichi J Shimada, Christopher P Cannon, Yuyin Liu, et al.
Circulation|March 2, 2017
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)Matthew A Cavender, William B White, Petr Jarolim, et al.
Muscle & Nerve|January 19, 2026
The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALSStacy A Rudnicki, Elisa Giacomelli, Katherine Herder, et al.
Hypertension (Dallas, Tex. : 1979)|August 3, 2016
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor AlogliptinWilliam B White, Craig A Wilson, George L Bakris, et al.
Lancet (London, England)|March 14, 2015
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trialFaiez Zannad, Christopher P Cannon, William C Cushman, et al.
European Journal of Heart Failure|July 18, 2024
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCMAhmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.
JAMA|April 2, 2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Journal of the American College of Cardiology|February 7, 2006
Predictors of adverse outcome among patients with hypertension and coronary artery diseaseCarl J Pepine, Peter R Kowey, Stuart Kupfer, et al.
European Journal of Heart Failure|March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trialAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
The New England Journal of Medicine|September 3, 2013
Alogliptin after acute coronary syndrome in patients with type 2 diabetesWilliam B White, Christopher P Cannon, Simon R Heller, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
American Heart Journal|May 16, 2016
Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trialYuichi J Shimada, Christopher P Cannon, Yuyin Liu, et al.
Circulation|March 2, 2017
Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)Matthew A Cavender, William B White, Petr Jarolim, et al.
Muscle & Nerve|January 19, 2026
The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALSStacy A Rudnicki, Elisa Giacomelli, Katherine Herder, et al.
Hypertension (Dallas, Tex. : 1979)|August 3, 2016
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor AlogliptinWilliam B White, Craig A Wilson, George L Bakris, et al.
Lancet (London, England)|March 14, 2015
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trialFaiez Zannad, Christopher P Cannon, William C Cushman, et al.
European Journal of Heart Failure|July 18, 2024
Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCMAhmad Masri, Roberto Barriales-Villa, Perry Elliott, et al.
JAMA|April 2, 2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Journal of the American College of Cardiology|February 7, 2006
Predictors of adverse outcome among patients with hypertension and coronary artery diseaseCarl J Pepine, Peter R Kowey, Stuart Kupfer, et al.
European Journal of Heart Failure|March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trialAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
The New England Journal of Medicine|September 3, 2013
Alogliptin after acute coronary syndrome in patients with type 2 diabetesWilliam B White, Christopher P Cannon, Simon R Heller, et al.
Pageof 10